Payment overview · 2025
General Payments
$566.07
31 reported records · 10 companies
Healthcare provider profile · identity verified
Michael John Murray, MD
Allopathic & Osteopathic Physicians|Family Medicine · REEDSVILLE, PA · NPI 1154344877
Verified facts
What the public records show
CMS Open Payments records show Michael John Murray, MD received $566.07 in general payments during 2025 across 31 reported records.
PFIZER INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.72 | 25.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.96 | 15.4% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $75.71 | 13.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.85 | 11.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.50 | 8.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.15 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.74 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.62 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.95 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.87 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.07 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $114.78 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $114.78 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $75.71 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.85 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.50 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.74 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $33.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
226 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 190 |
| Lisinopril | Lisinopril | 541 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 515 | 139 |
| Omeprazole | Omeprazole | 422 | 117 |
| Gabapentin | Gabapentin | 398 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 355 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 332 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 93 |
| Metformin Hcl | Metformin Hcl | 269 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 240 | 115 |
| Eliquis | Apixaban | 226 | 53 |
| Potassium Chloride | Potassium Chloride | 212 | 67 |
| Sertraline Hcl | Sertraline Hcl | 206 | 58 |
| Metformin Hcl Er | Metformin Hcl | 190 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 51 |
| Losartan Potassium | Losartan Potassium | 173 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 53 |
| Tramadol Hcl | Tramadol Hcl | 158 | 26 |
| Furosemide | Furosemide | 148 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 41 |
| Ozempic | Semaglutide | 140 | 30 |
| Finasteride | Finasteride | 134 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 133 | 30 |
| Famotidine | Famotidine | 129 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 34 |
| Clonazepam | Clonazepam | 125 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 35 |
| Ketoconazole | Ketoconazole | 111 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 33 |
| Meloxicam | Meloxicam | 105 | 16 |
| Prednisone | Prednisone | 98 | 71 |
| Ezetimibe | Ezetimibe | 97 | 29 |
| Allopurinol | Allopurinol | 94 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 26 |
| Carvedilol | Carvedilol | 88 | 27 |
| Pregabalin | Pregabalin | 88 | 14 |
| Simvastatin | Simvastatin | 87 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 23 |
| Lorazepam | Lorazepam | 83 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 45 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 79 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 21 |
| Montelukast Sodium | Montelukast Sodium | 77 | 20 |
| Jardiance | Empagliflozin | 71 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 57 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 19 |
| Glipizide Er | Glipizide | 65 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 23 |
| Buspirone Hcl | Buspirone Hcl | 64 | 15 |
| Trulicity | Dulaglutide | 63 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 14 |
| Valsartan | Valsartan | 58 | 20 |
| Amoxicillin | Amoxicillin | 57 | 38 |
| Celecoxib | Celecoxib | 57 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 57 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 23 |
| Atenolol | Atenolol | 55 | 17 |
| Azithromycin | Azithromycin | 55 | 51 |
| Chlorthalidone | Chlorthalidone | 55 | 15 |
| Alendronate Sodium | Alendronate Sodium | 54 | 16 |
| Mirtazapine | Mirtazapine | 52 | 16 |
| Nitroglycerin | Nitroglycerin | 52 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 14 |
| Torsemide | Torsemide | 52 | 18 |
| Spironolactone | Spironolactone | 51 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Topiramate | Topiramate | 47 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 47 | 16 |
| Colestipol Hcl | Colestipol Hcl | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 14 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 31 |
| Mupirocin | Mupirocin | 35 | 28 |
| Bupropion Xl | Bupropion Hcl | 32 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | 12 |
| Clotrimazole | Clotrimazole | 30 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | 12 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Temazepam | Temazepam | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Risperidone Er | Risperidone Microspheres | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.07 · 31 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, NURTEC ODT, Ozempic, PENMENVY, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error